News

NICE(UK): Acoramidis can be used, within its marketing authorisation, as an option to treat wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in…

NEW ORLEANS—An artificial intelligence model trained to analyze electrocardiogram (ECG) images identified which patients had transthyretin-mediated amyloid…

Key TakeawaysTransthyretin amyloid cardiomyopathy is increasingly diagnosed in the US (~120,000 affected), particularly among older adults and men, and remains…

Tafamidis treatment was associated with a significant reduction in the risk of ischemic stroke in patients with transthyretin-mediated amyloid cardiomyopathy…

Impact of disease-modifying therapies on imaging parameters in cardiac amyloidosis: A systematic review and meta-analysis.

Neuropathy followed by heart damage points to hATTRA rare mutation in the TTR gene — mutations in which are the cause of hereditary transthyretin amyloidosis (hATTR…

LOS ANGELES - Immix Biopharma, Inc. (NASDAQ:IMMX) announced today the completion of enrollment in its NEXICART-2 trial, a Phase 2 study evaluating CAR-T therapy NXC…

Open-Label Extension of the ATTRibute-CM Randomized Clinical TrialKey PointsQuestion  Is long-term treatment with acoramidis in transthyretin amyloid…

LOS ANGELES, CA, March 30, 2026 (GLOBE NEWSWIRE) — Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), the global leader in relapsed/refractory…

Analyses presented at ACC reinforce the totality of data for vutrisiran in patients with ATTR-CM including the impact on cardiovascular outcomes across a range of…